← Back
$COGT All transactions

Cogent Biosciences, Inc.

C

$ Value

Shares

7,000,000

Price

Filed

Mar 31

Insider

Name

Fairmount Funds Management LLC

Title

CIK

0001802528

Roles

Director

Transaction Details

Transaction Date

2026-03-31

Code

C

Table

Non-Derivative

Ownership

Indirect

Equity Swap

No

Shares After

12,503,418

Footnotes

Each share of Series A Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 250 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On March 31, 2026, the Reporting Persons converted 28,000 shares of Series A Convertible Preferred Stock into 7,000,000 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series A Convertible Preferred Stock. | Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Filing Info

Accession No.

0001104659-26-038057

Form Type

4

Issuer CIK

0001622229

Fairmount Funds Management LLC's History

Date Ticker Type Value
2026-03-31 COGT C
2026-03-31 COGT $242.6M
2026-03-31 COGT C $0
2026-03-31 ZBIO $3.0M
2026-03-23 DMRA A $0
2026-01-22 APGE $133.5M
2026-01-22 COGT $127.4M
2025-12-04 CBIO $18.2M
2025-12-04 CBIO $1.8M
2025-10-23 VRDN $10.0M

Other Insiders at COGT (90d)

Insider Bought Sold Last
Ferrante Karen Jean 2026-04-01
Fairmount Funds Management LLC $242.6M 2026-03-31